University of Michigan

Washington University

Johns Hopkins University

Christiane Wobus

Hollis Showalter

Herbert W Virgin

Moshe Talpaz

Stephanie Karst

Nicholas J Donato

David A Weitz

Roderick J Sorenson

Monika Ermann

Andrew B Feldman

Yafei Jin

Jeffrey S Lin

John Heyman

Kellogg Schwab

Jeffrey W Perry

Mary X O'Riordan

Timothy Julian

Matthew Young

Luke Peterson

Hollis D Showalter

Mary Xuan Dziem O'Riordan

H D Hollis Showalter

Mary Xuan Dziem O'riordan

Roderick Joseph Sorenson

Jeffrey William Perry

Mary Xuan O'riordan

Food products and/or pharmaceutical preparations including (i) viral neutralizing antibodies or antibody fragments anchored to a probiotic microorganism and (ii) a carrier medium for delivering the viral neutralizing antibodies or antibody fragments anchored to probiotic microorganisms to the gut of a mammal. Also provided are methods of making food products and/or pharmaceutical preparations, which can be used to treat existing viral infections or prevent the spread or transmission of viral infection.

Compositions and methods for preventing or relieving symptoms of infections

Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I). 

Deubiquitinase inhibitors and methods for use of the same

Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds, wherein the compound can have a structure of formula (III): 

A norovirus-permissive cell culture infected with a norovirus, and methods of culturing a norovirus, are disclosed. Norovirus-permissive cells include dendritic cell-lineage cells, and macrophage-lineage cells, such as dendritic cells, and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway. Also disclosed are methods of screening anti-viral compounds against norovirus-permissive cells infected with norovirus, and norovirus adapted to grow in fibroblasts as well as macrophages that are not deficient in a cellular anti-viral pathway. Methods of making a norovirus vaccine are also disclosed. A replicative form of norovirus as well as its use in the development of an anti-viral agent and a polypeptide expression system are also described. Further disclosed are methods of detecting norovirus in a sample.

Norovirus detection, methods and compositions therefor

A norovirus-permissive cell culture infected with a norovirus, and methods of culturing a norovirus, are disclosed. Norovirus-permissive cells include dendritic cell-lineage cells, and macrophage-lineage cells, such as dendritic cells, and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway. Also disclosed are methods of screening anti-viral compounds against norovirus-permissive cells infected with norovirus, and norovirus adapted to grow in fibroblasts as well as macrophages that are not deficient in a cellular anti-viral pathway. Methods of making a norovirus vaccine are also disclosed.

Norovirus infected cell cultures and uses therefor

Growing community of inventors

Dexter, MI, United States of America

Christiane Wobus